Deadlines are 5:00 PM (Eastern). No extensions will be granted.
|Letter of Intent||N/A|
|Application||Jun 29, 2022||Next|
|Award Notification||Jan 31, 2023|
|Earliest Start||Mar 01, 2023|
Background & Purpose
Important: Applications in the area of COMPLICATIONS will not be accepted. Applications in Psychosocial and Behavioral Health are welcome.
The Early Career Patient-Oriented Diabetes Research Award is intended for clinical researchers at a relatively early stage of their independent career. Clinical researchers who have received their first faculty-level appointment less than 5 years before the submission date are eligible to apply for this award. Applicants must have an MD, MD-PhD or PsyD, hold an appointment or joint appointment in a subspecialty of clinical medicine in a clinical department, and conduct human clinical research. In exceptional circumstances, non-MD candidates will be considered if their work is likely to contribute significantly to a clinical outcome.
For the purposes of this award, clinical research is defined as research conducted with human subjects for which the investigator directly interacts with the subjects.
There are no citizenship requirements for this program. To assure continued excellence and diversity among applicants and awardees, JDRF welcomes proposals from all qualified individuals and encourages proposals from persons with disabilities, women, and members of minority groups underrepresented in the sciences.
*Please contact JDRF Preaward Support with questions regarding eligibility.
The applicant must be sponsored by an investigator who is affiliated full-time with an accredited institution, who pursues clinical research, and who agrees to supervise the applicant’s training. The sponsor does not necessarily need to have a background in diabetes, but the research project must be type 1 diabetes-related and patient-oriented.
Research may be conducted at foreign and domestic, for-profit and nonprofit, and public and private organizations-such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.